Overview

A Diabetes Study to Treat A Population Previously Not at Target

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This study will assess if customizing the start dose of rosuvastatin appropriate for the degree of LDL-C reduction required, would achieve LDL-C target of ≤ 2.0 mmol/L quickly with either no titration or just one titration step after 6 weeks of therapy in type 2 diabetic patients previously treated with another statin and not at LDL-C targets.
Phase:
Phase 4
Details
Lead Sponsor:
AstraZeneca
Treatments:
Rosuvastatin Calcium